Vaxart Inc. (NASDAQ:VXRT) and Attwill Medical Solutions Sterilflow (AMS) have signed a memorandum of understanding affirming the parties’ intent to establish AMS lyophilization development resource as well as large scale manufacturing. These include the enteric coating and tableting for the oral COVID-19 vaccine of Vaxart.
Vaxart in MOU with Attwill Medial Solutions for production of COVID-19 vaccine
According to the MOU, AMS will assign dedicated equipment and resources for the scaling up and commercial manufacturing of the vaccine once the parties enter a formal agreement. Andrei Floroiu the CEO of Vaxart indicated that they are optimistic that AMS’s experience and ability to produce more than a billion doses per year will be beneficial to Vaxart’s CDMO group of partners. Floriou added that this will enable the company to ramp up manufacturing and ultimately supply its COVID-19 vaccine across Europe, the US, and other countries that will need the vaccine.
The CEO affirmed that they believe the oral vaccine generated from Vaxart’s proven platform will potentially offer superior protection against viral infections such as the SARS-CoV-2 virus. The vaccine works by triggering mucosal as well as systemic immunityby7 being delivered in a stable room temperature tablet. This is a huge logistical benefit, especially when dealing with large vaccination campaigns.
Vaxart vaccine selected to participate in the WARP program
On Friday, the company said its COVID-19 tablet had been picked to take part in the government-sponsored Operation Warp Speed Program. Vaxart, a clinical-stage biotechnology firm, stated that vaccine candidates will be part of the non-human primate challenge trial. The little know biotech has an oral vaccine instead of an injection, and it is the only oral vaccine candidate under evaluation in the Operation Warp Speed Program.
Although the company does not have any approved products for sale, yet it is among the small-cap stocks that have skyrocketed after announcing plans to develop a COVID-19 vaccine. The stock jumped almost 450% this week following the positive announcements about its vaccine candidate.